PDCD1 and non-small cell lung carcinoma: It has been shown that baseline corticosteroid use of the equivalent of ≥10 mg of prednisone was correlated with inferior clinical outcomes in NSCLC patients who were treated with a PD-1/PD-L1 blockade [135].